Ranbaxy markets 1st authorised generic in US
Ranbaxy Laboratories today announced the commercialisation of its first authorized generic (AG) product, Isoptin® SR (Verapamil Sit) in the US market.
According to an official release issued by the company to the BSE today, this has been effected through its wholly-owned subsidiary, Ranbaxy Pharmaceuticals Inc. (RPI), following an agreement with FSC Laboratories, Inc. of Charlotte, North Carolina, USA.
Commenting on the development, K Venkatachalam, VP & regional director (North America), Ranbaxy, said: "The commercialisation of Isoptin® SR heralds Ranbaxy’s entry into the authorised generics space. Isoptin® SR, a niche value added formulation, also enhances our new drug delivery systems (NDDS) capability and our efforts with other molecules, to improve patient compliance."
Verapamil, a calcium ion antagonist or channel blocker, is indicated for the management of hypertension and angina.The generic market for Verapamil SR is worth $122.2 million with limited competition primarily from 2 other players, the release said.
Ranbaxy Laboratories today announced the commercialisation of its first authorized generic (AG) product, Isoptin® SR (Verapamil Sit) in the US market.
According to an official release issued by the company to the BSE today, this has been effected through its wholly-owned subsidiary, Ranbaxy Pharmaceuticals Inc. (RPI), following an agreement with FSC Laboratories, Inc. of Charlotte, North Carolina, USA.
Commenting on the development, K Venkatachalam, VP & regional director (North America), Ranbaxy, said: "The commercialisation of Isoptin® SR heralds Ranbaxy’s entry into the authorised generics space. Isoptin® SR, a niche value added formulation, also enhances our new drug delivery systems (NDDS) capability and our efforts with other molecules, to improve patient compliance."
Verapamil, a calcium ion antagonist or channel blocker, is indicated for the management of hypertension and angina.The generic market for Verapamil SR is worth $122.2 million with limited competition primarily from 2 other players, the release said.